Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

NCT03214172 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03214172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03214172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
July 15, 2017
Completion date
September 15, 2017
Enrollment
1,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism